drugset / Trial / NCT06572319
Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens
NaSingle-groupOpen-labelTreatment
Summary
This trial is a single center, single arm, open label clinical study aimed at evaluating the efficacy and safety of the combination therapy of Disitamab Vedotin and trastuzumab in the treatment of advanced HER-2 positive gastric/gastroesophageal junction tumors
Timeline
- Start
- 2024-09-01
- Primary completion
- 2026-08-01
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | 2.5 mg/kg | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | 4 mg/kg | Intravenous |
| Background | Disitamab Vedotin | Monoclonal antibody | 2.5 mg/kg | Intravenous |